Literature DB >> 33575158

Clinical Presentation and Successful Management of an Infant With Down Syndrome and COVID-19 in Riyadh, Saudi Arabia.

Ibrahim Alsahabi1, Abdulaziz Alobaidi1, Ayman S Alahmari2, Noof Almohsen2, Abdullah H Alhamoud3,4.   

Abstract

Coronavirus is a serious, global disease. Down syndrome (DS) is characterized by immune dysregulation, has various anatomical variations, and is considered as comorbidity. These variations mean that children with DS are at risk of developing a severe case of COVID-19 if the virus is contracted. Here, we report the first case of COVID-19 in a four-month-old infant girl with DS and congenital heart disease (CHD) who was treated in Al-Imam Abdulrahman Al Faisal Hospital in the first health cluster in Riyadh, Saudi Arabia. The medical management and clinical outcome of the infant are reviewed. The infant was admitted after having received previous treatment from other hospitals, with a deteriorating condition. The patient had developed a rash, and oxygen support was required in addition to her baseline medication (furosemide and captopril). Ten days post admission, the patient's condition improved, and she became clinically stable. She was then discharged after two consecutive negative nasopharyngeal swabs. Based on the reported case, infants with DS and CHD should be considered a high-risk patient in terms of COVID-19 infection and require close observation.
Copyright © 2021, Alsahabi et al.

Entities:  

Keywords:  congenital heart disease; covid-19; down's syndrome; pediatric

Year:  2021        PMID: 33575158      PMCID: PMC7870114          DOI: 10.7759/cureus.13188

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  2 in total

1.  Clinical characteristics and comorbidities of COVID-19 in unvaccinated patients with Down syndrome: first year report in Brazil.

Authors:  Matheus Negri Boschiero; Camila Vantini Capasso Palamim; Fernando Augusto Lima Marson; Manoela Marques Ortega
Journal:  Hum Genet       Date:  2022-06-28       Impact factor: 5.881

2.  Specific Susceptibility to COVID-19 in Adults with Down Syndrome.

Authors:  Tomer Illouz; Arya Biragyn; Milana Frenkel-Morgenstern; Orly Weissberg; Alessandro Gorohovski; Eugene Merzon; Ilan Green; Florencia Iulita; Lisi Flores-Aguilar; Mara Dierssen; Ilario De Toma; Hefziba Lifshitz; Stylianos E Antonarakis; Eugene Yu; Yann Herault; Marie-Claude Potier; Alexandra Botté; Randall Roper; Benjamin Sredni; Ronit Sarid; Jacqueline London; William Mobley; Andre Strydom; Eitan Okun
Journal:  Neuromolecular Med       Date:  2021-03-04       Impact factor: 3.843

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.